Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq Other stock markets 02:30:00 22/01/2026 am IST			5-day change	1st Jan Change
11.60 ^USD	+6.72%		+6.72%	+12.08%

12/01	XOMA Royalty Corporation Announces CFO Changes, Effective January 12, 2026	CI
09/12	Cullinan Therapeutics, Inc. - Special Call

Transcript : Cullinan Therapeutics, Inc. - Special Call

Published on 12/09/2025 at 08:20 am IST - Modified on 12/09/2025 at 02:50 pm IST

S&P Capital IQ

Presenter Speech
Nadim Ahmed (Executives)

All right. Good evening, everyone. Thanks for coming as we look forward to discussing the compelling initial results for CLN-049 that were presented at ASH

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Cullinan Therapeutics, Inc.

12/01	XOMA Royalty Corporation Announces CFO Changes, Effective January 12, 2026	CI
09/12	Cullinan Therapeutics, Inc. - Special Call
09/12	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash Meeting	CI
08/12	Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses	MT
08/12	Cullinan Therapeutics says phase 1 CLN-049 monotherapy demonstrates promising efficacy	RE
01/12	Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia	CI
01/12	Cullinan Therapeutics receives FDA fast track designation for CLN-049	RE
01/12	Cullinan Therapeutics Investigational Acute Myeloid Leukemia Therapy Receives US FDA Fast-Track Designation	MT
22/11	Cullinan Therapeutics - Cullinan Amber notified MIT decision to terminate exclusive patent license agreement for CLN-617	RE
20/11	Cullinan, Taiho Submit New Drug Application for Zipalertinib in Lung Cancer	MT
20/11	Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics initiate rolling submission of new drug application to US FDA	RE
20/11	Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	CI
06/11	Cullinan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/11	Cullinan Therapeutics' Q3 net loss widens	RE
03/11	Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting	CI
25/25/25	Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025	CI
13/25/13	Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025	CI
10/25/10	Cullinan Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 08:30 AM
09/25/09	Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer	CI
07/25/07	Cullinan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
07/25/07	Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025	CI
07/25/07	Cullinan Therapeutics Q2 net loss widens to $70.1 mln on higher R&D costs	RE
14/25/14	Disc Medicine, Inc. Appoints Nadim Ahmed to Its Board of Directors	CI
30/25/30	Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index	CI
30/25/30	Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth Index	CI